REFERENCES
Adhanom Ghebreyesus, T (2020). WHO Director-General’s opening remarks at
the media briefing on COVID-19.
Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL,
et al. (2015). Efficacy and safety of ascending methotrexate dose in
combination with adalimumab: The randomised CONCERTO trial. Ann
Rheum Dis 74:1037–44.
Ceribelli A, Motta F, De Santis M, Ansari AA, Ridgway WM, Gershwin ME,
et al. (2020). Recommendations for coronavirus infection in rheumatic
diseases treated with biologic therapy. J Autoimmun 109:102442.
Chen N, Zhou M, Dong X, et al. (2020). Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in
Wuhan, China: a descriptive study. Lancet 395: 507‐513.
Chiu Y-M, Chen D-Y (2020). Infection risk in patients undergoing
treatment for inflammatory arthritis: non-biologics versus biologics.
Expert Rev Clin Immunol 16:207–28
Dong E, Du H, Gardner L (2020). An interactive web-based dashboard to
track COVID-19 in real time. Lancet Infect Dis 3099:19–20.
Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al.
(2020). Trials of anti-tumour necrosis factor therapy for COVID-19 are
urgently needed. Lancet. DOI:10.1016/S0140-6736(20)30858-8.
Fu B, Xu X, Wei H (2020). Why tocilizumab could be an effective
treatment for severe COVID-19? J Transl Med 18:164.
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al.
(2020). Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series
from New York. N Engl J Med. DOI:10.1056/NEJMc2009567.
Honkila M, Niinimäki R, Taskinen M, Kuismin O, Kettunen K, Saarela J, et
al. (2019). A nearly fatal primary Epstein-Barr virus infection
associated with low NK-cell counts in a patient receiving azathioprine:
a case report and review of literature. BMC Infect Dis 19:404.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020). Clinical
features of patients infected with 2019 novel coronavirus in Wuhan,
China. Lancet 395:497–506.
Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP
(2004). Differential effects of leflunomide and methotrexate on cytokine
production in rheumatoid arthritis. Ann Rheum Dis 63:1056‐1061.
Mehra MR, Desai SS, Ruschitzka F, Patel AN (2020). Articles
Hydroxychloroquine or chloroquine with or without a macrolide for
treatment of COVID-19: a multinational registry analysis. Lancet
6736(20):1–10.
Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, et
al. (2014). The natural history of influenza infection in the severely
immunocompromised vs non immunocompromised hosts. Clin Infect Dis
58:214-24.
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. (2020).
Renin-angiotensin system inhibitors improve the clinical outcomes of
COVID-19 patients with hypertension. Emerg Microbes Infect 9:757–60.
Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E,
Pascual-Pastor M, et al. (2020). Incidence of COVID-19 in a cohort of
adult and paediatric patients with rheumatic diseases treated with
targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Semin Arthritis Rheum 50:564–70.
Mizumoto K, Kagaya K, Zarebski A, Chowell G. (2020). Estimating the
asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on
board the Diamond Princess cruise ship, Yokohama, Japan.
Eurosurveillance. [Online] Available fromhttps://www.eurosurveillance.org/content/10.2807/1560-
7917.ES.2020.25.10.2000180 [Accessed 18th April 2020].
Nasuno M, Miyakawa M, Tanaka H, Motoya S (2017). Short-and Long-Term
Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative
Colitis and Related Prognostic Factors: A Single-Center Retrospective
Study. Digestion 95:67–71.
Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, et
al. (2020). Estimation of the asymptomatic ratio of novel coronavirus
infections (COVID-19). Int J Infect Dis 94:154-155.
Ruiz-Irastorza G, Danza A, Khamashta M (2012). Glucocorticoid use and
abuse in SLE. Rheumatol 51:1145–53.
Sawalha AH, Zhao M, Coit P, Lu Q (2020). Epigenetic dysregulation of
ACE2 and interferon-regulated genes might suggest increased COVID-19
susceptibility and severity in lupus patients. Clin Immunol 215:108410.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. (2020).
Hydroxychloroquine in patients with COVID-19: an open-label, randomized,
controlled trial. MedRxiv. DOI:10.1101/2020.04.10.
Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S,
Petersson IF, et al. (2012). Conventional combination treatment versus
biological treatment in methotrexate-refractory early rheumatoid
arthritis: 2 Year follow-up of the randomised, non-blinded,
parallel-group Swefot trial. Lancet 379:1712–20.
Vom Steeg LG, Klein SL (2019). Sex and sex steroids impact influenza
pathogenesis across the life course. Semin Immunopathol 41:189–194.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. (2020). Clinical
Characteristics of 138 Hospitalized Patients with 2019 Novel
Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323:1061–1069.
Wu Z, Mc Googan JM. (2020). Characteristics of and Important Lessons
from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary
of a Report of 72 314 Cases from the Chinese Center for Disease Control
and Prevention. JAMA 323:1239-1242.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of
severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci.
DOI:10.1073/pnas.20056151171.
Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. (2020). The use of
anti-inflammatory drugs in the treatment of people with severe
coronavirus disease 2019 (COVID-19): The experience of clinical
immunologists from China. Clin Immunol 214:108393.
Zhong J, Tang J, Ye C, Dong L (2020) The immunology of COVID-19: is
immune modulation an option for treatment? Lancet Rheumatol.
DOI:10.1016/S2665-9913(20)30120-X.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course
and risk factors for mortality of adult inpatients with COVID-19 in
Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062.
Erratum in: Lancet 395:1038.